Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.
Our MPPs are selectively-sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus.
Read More »
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Jul 25, 2017|
Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option
|Jul 20, 2017|
Kala Pharmaceuticals Announces Pricing of Initial Public Offering
|May 1, 2017|
Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery
|There are currently no events scheduled.|